Lytic domain fusion constructs and methods of making and using same
AssigneesBoard of Supervisors of Louisiana State University and Agricultural and Mechanical College, Esperance Pharmaceuticals, Inc.
InventorsCarola Leuschner, Hector Alila
Life of this patent
Estimating the term…
Abstract
The invention relates to fusion constructs, methods of using fusion constructs and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies.
Claims43
A fusion construct comprising a first lytic domain and a second domain, wherein said first lytic domain consists of peptide KFAKFAKKFAKFAKKFA (SEQ ID NO:3), or KFAKFAKKFAKFAKKFAKF (SEQ ID NO.5) or KFAKFAKKFAKFAKKFAKFA (SEQ ID NO.6);
- and said second domain comprises a binding moiety, wherein the binding moiety comprises a luteinizing hormone releasing hormone (LHRH), a LHRH analogue, a fragment of a LHRH, or a fragment of a LHRH analogue that binds to a LHRH receptor, or wherein the binding moiety comprises a chorionic gonadotropin beta subunit (β-CG), a β-CG analogue, a fragment of a β-CG or a β-CG analogue that binds to a luteinizing hormone (LH)/chorionic gonadotropin (CG) receptor.
An isolated or purified peptide consisting of KFAKFAKKFAKFAKKFA (SEQ ID NO:3), KFAKFAKKFAKFAKKFAKF (SEQ ID NO:5) or KFAKFAKKFAKFAKKFAKFA (SEQ ID NO:6).
Dependencies are inferred from the claim text.